Activity of mecillinam against USA urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibiotics
Objectives: To support the clinical development of mecillinam and pivmecillinam in the United States for the treatment of complicated and uncomplicated urinary tract infections (UTIs), this study investigated the activity of mecillinam compared with other antibiotics against Enterobacterales isolate...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Global Antimicrobial Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716524001656 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846113148125315072 |
|---|---|
| author | Stephen Hawser Ian Morrissey Nimmi Kothari Federica Monti Anne Santerre Henriksen |
| author_facet | Stephen Hawser Ian Morrissey Nimmi Kothari Federica Monti Anne Santerre Henriksen |
| author_sort | Stephen Hawser |
| collection | DOAJ |
| description | Objectives: To support the clinical development of mecillinam and pivmecillinam in the United States for the treatment of complicated and uncomplicated urinary tract infections (UTIs), this study investigated the activity of mecillinam compared with other antibiotics against Enterobacterales isolates from patients with UTIs in the United States during 2017 to 2020. Mecillinam is a first-in-class amidinopenicillin antibiotic, being the only β-lactam to exert its antibacterial activity through exclusive binding to penicillin-binding protein 2. Pivmecillinam is the oral prodrug of mecillinam and is recommended as a first-line therapy by the Infectious Disease Society of America guidelines for uncomplicated UTIs and is approved for the treatment of uncomplicated UTIs in Europe, Canada, and the United States. Methods: A total of 3303 isolates were collected and antimicrobial susceptibility determined according to Clinical Laboratory and Standards Institute (CLSI) guidelines. Results: Susceptibility was highest for fosfomycin (97.1% susceptible) and mecillinam (94.9% susceptible). Against extended-spectrum beta-lactamase (ESBL)-positive bacteria susceptibilities were highest for mecillinam (98.2% susceptible) and fosfomycin (97.3% susceptible) and against ESBL-positive K. pneumoniae only mecillinam and fosfomycin had > 80% susceptibility. Resistance to comparator antibiotics was highest for trimethoprim-sulfamethoxazole (27.1%), followed by ciprofloxacin (19.3%), ceftriaxone (19.2%), and nitrofurantoin (12.1%). Multi-drug-resistant isolates were most susceptible to mecillinam and fosfomycin. Conclusion: The data further support the clinical development and clinical utility of mecillinam. © 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. |
| format | Article |
| id | doaj-art-6e9d55a0a13e443ea1cb7d6df3a0ff7e |
| institution | Kabale University |
| issn | 2213-7165 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Global Antimicrobial Resistance |
| spelling | doaj-art-6e9d55a0a13e443ea1cb7d6df3a0ff7e2024-12-22T05:28:00ZengElsevierJournal of Global Antimicrobial Resistance2213-71652024-12-0139137143Activity of mecillinam against USA urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibioticsStephen Hawser0Ian Morrissey1Nimmi Kothari2Federica Monti3Anne Santerre Henriksen4IHMA Europe Sàrl, Monthey/VS, Switzerland; Corresponding author. Mailing address: IHMA Europe Sàrl, Route de I'Ile-au-Bois 1A, 1870 Monthey, Switzerland.Antimicrobial Focus Ltd., Sawbridgeworth, Hertfordshire, UKIHMA Europe Sàrl, Monthey/VS, SwitzerlandIHMA Europe Sàrl, Monthey/VS, SwitzerlandMaxel Consulting ApS, Jyllinge, DenmarkObjectives: To support the clinical development of mecillinam and pivmecillinam in the United States for the treatment of complicated and uncomplicated urinary tract infections (UTIs), this study investigated the activity of mecillinam compared with other antibiotics against Enterobacterales isolates from patients with UTIs in the United States during 2017 to 2020. Mecillinam is a first-in-class amidinopenicillin antibiotic, being the only β-lactam to exert its antibacterial activity through exclusive binding to penicillin-binding protein 2. Pivmecillinam is the oral prodrug of mecillinam and is recommended as a first-line therapy by the Infectious Disease Society of America guidelines for uncomplicated UTIs and is approved for the treatment of uncomplicated UTIs in Europe, Canada, and the United States. Methods: A total of 3303 isolates were collected and antimicrobial susceptibility determined according to Clinical Laboratory and Standards Institute (CLSI) guidelines. Results: Susceptibility was highest for fosfomycin (97.1% susceptible) and mecillinam (94.9% susceptible). Against extended-spectrum beta-lactamase (ESBL)-positive bacteria susceptibilities were highest for mecillinam (98.2% susceptible) and fosfomycin (97.3% susceptible) and against ESBL-positive K. pneumoniae only mecillinam and fosfomycin had > 80% susceptibility. Resistance to comparator antibiotics was highest for trimethoprim-sulfamethoxazole (27.1%), followed by ciprofloxacin (19.3%), ceftriaxone (19.2%), and nitrofurantoin (12.1%). Multi-drug-resistant isolates were most susceptible to mecillinam and fosfomycin. Conclusion: The data further support the clinical development and clinical utility of mecillinam. © 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.http://www.sciencedirect.com/science/article/pii/S2213716524001656MethicillinEnterobacteralesEsblGram-negativeUnited StatesResistance |
| spellingShingle | Stephen Hawser Ian Morrissey Nimmi Kothari Federica Monti Anne Santerre Henriksen Activity of mecillinam against USA urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibiotics Journal of Global Antimicrobial Resistance Methicillin Enterobacterales Esbl Gram-negative United States Resistance |
| title | Activity of mecillinam against USA urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibiotics |
| title_full | Activity of mecillinam against USA urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibiotics |
| title_fullStr | Activity of mecillinam against USA urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibiotics |
| title_full_unstemmed | Activity of mecillinam against USA urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibiotics |
| title_short | Activity of mecillinam against USA urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibiotics |
| title_sort | activity of mecillinam against usa urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibiotics |
| topic | Methicillin Enterobacterales Esbl Gram-negative United States Resistance |
| url | http://www.sciencedirect.com/science/article/pii/S2213716524001656 |
| work_keys_str_mv | AT stephenhawser activityofmecillinamagainstusaurinarytractclinicalisolatesfrom2017to2020includingisolatesresistanttocomparatorantibiotics AT ianmorrissey activityofmecillinamagainstusaurinarytractclinicalisolatesfrom2017to2020includingisolatesresistanttocomparatorantibiotics AT nimmikothari activityofmecillinamagainstusaurinarytractclinicalisolatesfrom2017to2020includingisolatesresistanttocomparatorantibiotics AT federicamonti activityofmecillinamagainstusaurinarytractclinicalisolatesfrom2017to2020includingisolatesresistanttocomparatorantibiotics AT annesanterrehenriksen activityofmecillinamagainstusaurinarytractclinicalisolatesfrom2017to2020includingisolatesresistanttocomparatorantibiotics |